ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Johnson & Johnson is consolidating its West Coast pharmaceutical operations as part of an overall realignment of its drug business. The Fremont, Calif., research facility of J&J's biopharma subsidiary Scios will be closed. R&D programs will be shifted to J&J's Pharmaceutical Research & Development site in La Jolla, Calif., and to the Mountain View, Calif., campus of another J&J subsidiary, Alza. The moves will result in the loss of about 500 jobs across Scios and Alza. Earlier this year, J&J said it would close its Raritan, N.J., drug discovery unit, shedding 280 positions at the site (C&EN, Feb. 27, page 6).
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X